alpha4beta2-nicotinic receptor binding with 5-IA in Alzheimer's disease: methods of scan analysis
| Autor: | Jonathan J.K. Best, David J. Wyper, Lucie L. Herrmann, Emma Terrière, James Patterson, Claire Donaghey, Marion Strachan, Nadine Dougall, Klaus P. Ebmeier, Sally L. Pimlott, Jane A. Lonie, Mike Sharman |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2008 |
| Předmět: |
Male
Pathology medicine.medical_specialty Neurology Pyridines medicine.drug_class Pilot Projects Neuropsychological Tests Receptors Nicotinic Pharmacology Biochemistry Cellular and Molecular Neuroscience Piperidines Alzheimer Disease Image Processing Computer-Assisted medicine Humans Dementia Donepezil Neurochemistry Receptor Nootropic Agents Aged Aged 80 and over Observer Variation Tomography Emission-Computed Single-Photon Brain General Medicine Ligand (biochemistry) medicine.disease Nicotinic agonist Acetylcholinesterase inhibitor Indans Azetidines Female Cholinesterase Inhibitors Radiopharmaceuticals Psychology medicine.drug |
| Zdroj: | Neurochemical research. 33(4) |
| ISSN: | 1573-6903 0364-3190 |
| Popis: | Five patients with Alzheimer's disease and five healthy volunteers were examined by SPECT with the nicotinic receptor ligand 123I-5-IA-85380. Patients were scanned before and after 6 weeks of treatment with donepezil. Quantification by regions of interest was reliable and the optimal normalisation procedure used cerebellar ratios. We found relative reductions in 5-IA binding capacity in patients in thalamus, frontal and central regions of interest of approximately one standard deviation unit (Cohen's d = 1). Reductions in binding after treatment with the acetylcholinesterase inhibitor donepezil of the same magnitude occurred in the brain stem. The study was clearly too small to confirm group differences, but it suggests that 5-IA can be used to examine both group differences and treatment effects in patients with Alzheimer's disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink